At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 161 enrolled
Drug / intervention
SLS-005 +1 moredrug
Likely dose
SLS-005 0.75 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
In Brief
A Phase 3 clinical trial evaluating SLS-005 and Matching Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 161 participants across 1 site.
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsSeelos Therapeutics, Inc.
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartFeb 2022
Primary CompletionAug 2023
TodayJul 2026
First PostedNov 29, 2021
Enrollment StartFeb 21, 2022
Primary CompletionAug 25, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.6 years ago
Interventions
SLS-005drug
Administration: Infusion Dose: 0.75 g/kg weekly
Matching Placebodrug
Administration: Infusion Dose: equivalent weight-based volume as described for trehalose